0001104659-21-133122.txt : 20211102 0001104659-21-133122.hdr.sgml : 20211102 20211102170644 ACCESSION NUMBER: 0001104659-21-133122 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20211102 DATE AS OF CHANGE: 20211102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CPG Cooper Square International Equity, LLC CENTRAL INDEX KEY: 0001818255 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-239925 FILM NUMBER: 211372376 BUSINESS ADDRESS: STREET 1: C/O CENTRAL PARK ADVISERS, LLC STREET 2: 500 FIFTH AVENUE, 31ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10110 BUSINESS PHONE: 212-317-9200 MAIL ADDRESS: STREET 1: C/O CENTRAL PARK ADVISERS, LLC STREET 2: 500 FIFTH AVENUE, 31ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10110 424B3 1 tm2130875d4_424b3.htm 424B3

 

  Filed pursuant to Rule 424(b)(3)
  File No. 333-239925

 

CPG COOPER SQUARE INTERNATIONAL EQUITY, LLC

 

SUPPLEMENT TO THE PROSPECTUS

AND STATEMENT OF ADDITIONAL INFORMATION

 

NOVEMBER 2021

 

 

 

Class A Units

Class I Units

 

 

 

The information set forth below supplements and supersedes any contrary information contained in the Prospectus and Statement of Additional Information ("SAI"), each dated October 1, 2020, of CPG Cooper Square International Equity, LLC (the "Fund"). Prospective Investors are urged to read carefully the Fund's Prospectus and Limited Liability Company Agreement, as amended and restated from time to time. The Prospectus and SAI are published on the Fund's website (http://www.coopersquarefund.com). The SAI also is available upon request and without charge by writing the Fund at its principal office, or by calling (collect) (212) 317-9200.

 

Capitalized terms not otherwise defined herein shall have the same meaning as provided in the Prospectus. If the prospective Investor wishes to invest in the Fund, the Investor must complete, execute and return the Fund's Investor Certificate.

 

*      *      *

 

The Adviser and the Sub-Adviser have agreed to extend the Expense Limitation and Reimbursement Agreement with the Fund until February 1, 2023.